Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study : A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program
© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: The Swiss HCVree Trial (NCT02785666) was conducted in 2015-2017 with the goal of implementing a population-based systematic hepatitis C virus (HCV) micro-elimination program among men who have sex with men (MSM) with human immunodeficiency virus (HIV) enrolled in the Swiss HIV Cohort Study (SHCS). The trial led to a 91% and 77% decline of HCV prevalence and incidence, respectively. The long-term effect of this HCV micro-elimination program is yet to be explored.
METHODS: All MSM enrolled in the SHCS were screened for HCV RNA using stored plasma samples obtained in 2019, termed "Swiss HCVree Post" screen. The incidence of HCV infection over time was assessed using additional information on HCV testing routinely collected in the SHCS. Characteristics of participants with replicating HCV infection were analyzed.
RESULTS: The point-prevalence of "Swiss HCVree Post" (N = 4641) was 0.6%, reflecting a decline of 48% compared to the end of the Swiss HCVree Trial where the prevalence was 1.2%. Further, the incidence of HCV among MSM in the SHCS declined from 0.31/100 person-years (py) (95% confidence interval [CI] [.17, .55]) in 2017 to 0.19/100 py (95% CI [.09, .39]) in 2019.
CONCLUSIONS: A systematic HCV RNA-based screening among MSM with HIV conducted 2 years after the Swiss HCVree Trial revealed a sustained effect and further decline of the prevalence and incidence of replicating HCV infection. This indicates that the Swiss HCVree Trial was successful in curbing the HCV epidemic among MSM with HIV in Switzerland.
CLINICAL TRIALS REGISTRATION: NCT02785666.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 75(2022), 10 vom: 14. Nov., Seite 1723-1731 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kusejko, Katharina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
63231-63-0 |
|---|
| Anmerkungen: |
Date Completed 16.11.2022 Date Revised 19.12.2022 published: Print ClinicalTrials.gov: NCT02785666 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac273 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339340029 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339340029 | ||
| 003 | DE-627 | ||
| 005 | 20231226002659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac273 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339340029 | ||
| 035 | |a (NLM)35404384 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kusejko, Katharina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study |b A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2022 | ||
| 500 | |a Date Revised 19.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02785666 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: The Swiss HCVree Trial (NCT02785666) was conducted in 2015-2017 with the goal of implementing a population-based systematic hepatitis C virus (HCV) micro-elimination program among men who have sex with men (MSM) with human immunodeficiency virus (HIV) enrolled in the Swiss HIV Cohort Study (SHCS). The trial led to a 91% and 77% decline of HCV prevalence and incidence, respectively. The long-term effect of this HCV micro-elimination program is yet to be explored | ||
| 520 | |a METHODS: All MSM enrolled in the SHCS were screened for HCV RNA using stored plasma samples obtained in 2019, termed "Swiss HCVree Post" screen. The incidence of HCV infection over time was assessed using additional information on HCV testing routinely collected in the SHCS. Characteristics of participants with replicating HCV infection were analyzed | ||
| 520 | |a RESULTS: The point-prevalence of "Swiss HCVree Post" (N = 4641) was 0.6%, reflecting a decline of 48% compared to the end of the Swiss HCVree Trial where the prevalence was 1.2%. Further, the incidence of HCV among MSM in the SHCS declined from 0.31/100 person-years (py) (95% confidence interval [CI] [.17, .55]) in 2017 to 0.19/100 py (95% CI [.09, .39]) in 2019 | ||
| 520 | |a CONCLUSIONS: A systematic HCV RNA-based screening among MSM with HIV conducted 2 years after the Swiss HCVree Trial revealed a sustained effect and further decline of the prevalence and incidence of replicating HCV infection. This indicates that the Swiss HCVree Trial was successful in curbing the HCV epidemic among MSM with HIV in Switzerland | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: NCT02785666 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HCV elimination | |
| 650 | 4 | |a HIV/HCV-coinfection | |
| 650 | 4 | |a MSM | |
| 650 | 4 | |a micro-elimination | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 700 | 1 | |a Salazar-Vizcaya, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Stöckle, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Béguelin, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Schmid, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Ongaro, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Darling, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Bernasconi, Enos |e verfasserin |4 aut | |
| 700 | 1 | |a Rauch, Andri |e verfasserin |4 aut | |
| 700 | 1 | |a Kouyos, Roger D |e verfasserin |4 aut | |
| 700 | 1 | |a Günthard, Huldrych F |e verfasserin |4 aut | |
| 700 | 1 | |a Böni, Jürg |e verfasserin |4 aut | |
| 700 | 1 | |a Fehr, Jan S |e verfasserin |4 aut | |
| 700 | 1 | |a Braun, Dominique L |e verfasserin |4 aut | |
| 700 | 0 | |a Swiss HIV Cohort Study |e verfasserin |4 aut | |
| 700 | 1 | |a Abela, I |e investigator |4 oth | |
| 700 | 1 | |a Aebi-Popp, K |e investigator |4 oth | |
| 700 | 1 | |a Anagnostopoulos, A |e investigator |4 oth | |
| 700 | 1 | |a Battegay, M |e investigator |4 oth | |
| 700 | 1 | |a Bernasconi, E |e investigator |4 oth | |
| 700 | 1 | |a Braun, D L |e investigator |4 oth | |
| 700 | 1 | |a Bucher, H C |e investigator |4 oth | |
| 700 | 1 | |a Calmy, A |e investigator |4 oth | |
| 700 | 1 | |a Cavassini, M |e investigator |4 oth | |
| 700 | 1 | |a Ciuffi, A |e investigator |4 oth | |
| 700 | 1 | |a Dollenmaier, G |e investigator |4 oth | |
| 700 | 1 | |a Egger, M |e investigator |4 oth | |
| 700 | 1 | |a Elzi, L |e investigator |4 oth | |
| 700 | 1 | |a Fehr, J |e investigator |4 oth | |
| 700 | 1 | |a Fellay, J |e investigator |4 oth | |
| 700 | 1 | |a Furrer, H |e investigator |4 oth | |
| 700 | 1 | |a Fux, C A |e investigator |4 oth | |
| 700 | 1 | |a Günthard, H F |e investigator |4 oth | |
| 700 | 1 | |a Hachfeld, A |e investigator |4 oth | |
| 700 | 1 | |a Haerry, D |e investigator |4 oth | |
| 700 | 1 | |a Hasse, B |e investigator |4 oth | |
| 700 | 1 | |a Hirsch, H H |e investigator |4 oth | |
| 700 | 1 | |a Hoffmann, M |e investigator |4 oth | |
| 700 | 1 | |a Hösli, I |e investigator |4 oth | |
| 700 | 1 | |a Huber, M |e investigator |4 oth | |
| 700 | 1 | |a Kahlert, C R |e investigator |4 oth | |
| 700 | 1 | |a Kaiser, L |e investigator |4 oth | |
| 700 | 1 | |a Keiser, O |e investigator |4 oth | |
| 700 | 1 | |a Klimkait, T |e investigator |4 oth | |
| 700 | 1 | |a Kouyos, R D |e investigator |4 oth | |
| 700 | 1 | |a Kovari, H |e investigator |4 oth | |
| 700 | 1 | |a Kusejko, K |e investigator |4 oth | |
| 700 | 1 | |a Martinetti, G |e investigator |4 oth | |
| 700 | 1 | |a Martinez de Tejada, B |e investigator |4 oth | |
| 700 | 1 | |a Marzolini, C |e investigator |4 oth | |
| 700 | 1 | |a Metzner, K J |e investigator |4 oth | |
| 700 | 1 | |a Müller, N |e investigator |4 oth | |
| 700 | 1 | |a Nemeth, J |e investigator |4 oth | |
| 700 | 1 | |a Nicca, D |e investigator |4 oth | |
| 700 | 1 | |a Paioni, P |e investigator |4 oth | |
| 700 | 1 | |a Pantaleo, G |e investigator |4 oth | |
| 700 | 1 | |a Perreau, M |e investigator |4 oth | |
| 700 | 1 | |a Rauch, A |e investigator |4 oth | |
| 700 | 1 | |a Schmid, P |e investigator |4 oth | |
| 700 | 1 | |a Speck, R |e investigator |4 oth | |
| 700 | 1 | |a Stöckle, M |e investigator |4 oth | |
| 700 | 1 | |a Tarr, P |e investigator |4 oth | |
| 700 | 1 | |a Trkola, A |e investigator |4 oth | |
| 700 | 1 | |a Wandeler, G |e investigator |4 oth | |
| 700 | 1 | |a Yerly, S |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 75(2022), 10 vom: 14. Nov., Seite 1723-1731 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2022 |g number:10 |g day:14 |g month:11 |g pages:1723-1731 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac273 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2022 |e 10 |b 14 |c 11 |h 1723-1731 | ||